R. Marshall Austin, MD, PhD
Professor of Pathology

Dr. Austin is Medical Director of Cytopathology and staff pathologist in Gynecologic and Breast Surgical Pathology. Dr. Austin oversees the weekly Gynecologic Oncology tumor board held in conjunction with Gynecologic Oncvology. Dr. Austin's research focus over the past several decades has been on cervical screening, risk stratification, and risk management.

Office Location:
Pathology Department
Room 4427
Magee-Womens Hospital
300 Halket Street
Pittsburgh, PA 15213

Contact Information:
Office Telephone: 412-641-3347
Office Fax: 412-641-1675
Lab Phone: 412-641-3341
Pager: 412-917-9769
Email Address: raustin@magee.edu

Education

  • PhD - Duke University, 1976
  • MD - Duke University, 1977

Research Interests

  • Risk Management in Cervical Cancer Screening
  • Gynecological Cytopathology
  • New Technology Enhancements for Cervical Cancer Screening

Certifications

AP/CP (1981) with voluntary recertification extended to 2024; Cytopathology (1990); Medical Microbiology (1983)

Specialties

Cytopathology, Gynecologic and Breast Pathology

Awards and Honors

  • 2014 Papanicolaou Award, American Society of Cytopathology
  • Best Doctors Award - Pittsburgh Magazine, 2012, 2013
  • Best Doctors in America Award, 2005-2013
  • College of American Pathologists - William E. Kuehn Outstanding Communicator Award, 2001
  • College of American Pathologists - Presidentís Award, 1997

Clinical Experties

Dr. Austin is an experienced specialist in Cytopathology and Gynecologic and Breast Pathology. Dr. Austin has published extensively over the past decade on the performance of cervical screening tests in the Magee Womens Hospital Laboratory, one of the country's largest academic hospital cervical screening facilities. Dr. Austin received subspecialty postgraduate training in Gynecologic and Breast Surgical Pathology and Cytopathology at the Armed Forces Institute of Pathology (1983-1986) and is past-President of the American Society of Cytopathology (2004-2005). Dr. Austin also completed graduate (PhD) training in Virology at Duke University (1972-1976) and has published extensively on Human Papillomavirus testing in cervical screening.

Selected Publications

View Dr. Austin's publications on PubMed

  1. Heider A, Austin RM, Zhao C. HPV Test Results Stratify Risk for Histopathologic Follow-up Findings of High Grade Cervical Intraepithelial Neoplasia in Women with LSIL Pap Results. Acta Cytologica 2011; 55 48-53.
  2. Zhao C, Kalposi-Novak P, Austin RM. Follow-up Findings in Adolescents with HSIL Pap test Results. Archives of Pathology and Laboratory Medicine 2011; 135:361-364.
  3. Pantanowitz L, Onisko A, Austin RM. Screening for Cervical cancer Using Data. Critical Values 2011; 4: 20-22.
  4. Austin RM, Zhao C. Observations on Pap Test Litigation. Pathology Case Reviews 2011; 16: 73-82.
  5. McBee WC, Gardner A, Edwards RP, Lesnock J, Bhargava R, Austin RM, Guidos R, Khan S. MicroRNA Analysis in Human Papillomavirus (HPV)-Associated Cervical Neoplasia and Cancer. Journal of Carcinogenesis & Mutagenesis 2011; 2:1 http://dx.doi.org/4172/2157-2518.1000114
  6. Gao FF, Khalbuss WE, Austin RM, Monaco SE. Fine Needle Aspiration Findings of Crystal Storing Histiocytosis in the Breast Associated with Lymphoma. Acta Cytologica 2011; 55: 302-306.
  7. Zhao C, Chen X, Onisko A, Kanbour A, Austin RM. Follow-up outcomes for a large cohort of U.S. women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. Gynecologic Oncology 2011; 122: 291-296.
  8. Gao FF, Austin RM, Zhao C. Histopathologic Follow-up and Human Papillomavirus DNA Test Results in 290 Patients with High Grade Squamous Intraepithelial Lesion Papanicolaou Test Results. Cancer Cytopathol. 2011; 119: 377-386.
  9. Austin RM, Zhao C. Unrecognized Risks Associated with New Cervical Screening Guidelines for Younger Women. Archives of Pathology and Laboratory Medicine 2011; 135: 1080.
  10. Bansal M, Austin RM, Zhao C. Correlation of Histopathologic Follow-up Findings with Vaginal Human Papillomavirus and LSIL Pap Test Results. Archives of Pathology and Laboratory Medicine 2011; 1545-1549.
  11. Zhao C, Domfex A, Austin RM. Histopathologic Outcomes and Clinical Correlations For High Risk Patients Screened with Anal Cytology. Acta Cytologica 2012; 56: 62-67.
  12. Austin RM, Zhao C. Type 1 and Type 2 Cervical Carcinomas: Some Cervical Carcinomas Are More Difficult to Prevent with Screening. Cytopathology 2012; 23: 6-12.
  13. Austin RM. ATHENA Trial CIN2+ Cervical Biopsy Misclassifications Raise Questions. American Journal of Clinical Pathology 2012; 137: 1012-1014.
  14. Skaznik-Wikiel M, Sukumvanich P, Austin RM, Zorn K, Krivak T, Edwards RP, Olawaiye AB. Cervical cancer screening in elderly patients: Should screening be discontinued at age 70? Acta Cytologica 2012. 56: 388-393.
  15. Li Z, Austin RM, Guo M, Zhao C. Screening Test Results Associated with Cancer Diagnoses in 287 Patients with Cervical Squamous Carcinoma. Archives of Pathology and Laboratory Medicine 2012; 136: 1533-1540.
  16. Cohen D, Austin RM, Gilbert C, Freij R, Zhao C. Follow-up Outcomes in a Large Cohort of Patients with Human Papillomavirus-Negative ASC-H Cervical Screening Test Results. American Journal of Clinical Pathology 2012; 138: 517-523.
  17. Austin RM, Zhao C. How should "negative" HPV LDT results be verified? American Journal of Clinical Pathology 2012; 138: 619-622.
  18. Naryshkin S, Austin RM. Limitations of Widely Used Human Papillomavirus Laboratory Developed Testing in Cervical Screening. Drug, Healthcare, and Patient Safety 2012; 4: 1-7.
  19. Zhao C, Weng B, Li Z, Yang H, Austin RM. Follow-up outcomes of a large cohort of low-risk women with negative liquid-based cytology and negative HPV test results. Am J Clin Pathol 2013; 139: 32-38.
  20. Nance KV, Naryshkin S, Austin RM. Limitations of Widely Used Human Papillomavirus Laboratory Developed Testing in Cervical Screening. Drug, Healthcare, and Patient Safety 2013; 5: 1-3.
  21. Clary KM, Davey DD, Naryshkin S, Austin RM, Chmara BA, Tworek J. The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations prior to sign- out, and turn-around-time in gynecologic quality assurance: Findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference. Working Group 1. Archives of Pathology and Laboratory 2013; 137:164-174.
  22. Nance KV, Naryshkin S, Austin RM. Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath liquid-based specimens. Drug, Healthcare, and Patient Safety 2013; 5: 101-104.
  23. Rodriguez EF, Monaco SE, Austin R M, Khalbuss W, Pantanowitz L. Abdominopelvic Washings: A Comprehensive Review. Cytojournal 2013; 10:7.
  24. Zhao C, Li Z, Austin RM. Cervical Screening Test Results Associated with 265 Histopathologic Diagnoses of Cervical Glandular Neoplasia. American Journal of Clinical Pathology 2013; 140: 47-54.
  25. Zhao C, Amin M, Weng B, Chen X, Kanbour-Shakir A, Austin RM. Cytology and HPV Screening Test Results Associated with 2827 Histopathologic Cervical Intraepithelial Neoplasia 2/3 Diagnoses. Arch Pathol Lab Med 2013; 137: 942-947.
  26. Elsheikh TM, Austin RM, Chhieng DF, Miller FS, Moriarty AT, Renshaw AA. American Society of Cytopathology workload recommendations for automated Pap test screening: Developed by the productivity and quality assurance in the era of automated screening task force. Diagn Cytopathol 2013; 41:174-178.
  27. Rodriguez E, Lum D, Guido R, Austin RM. Cytologic Findings in Experimental In Vivo Fallopian Tube Brush Specimens. Acta Cytologica 2013; 57: 611-618.
  28. Baron S, Li Z, Austin RM, Zhao C. Low Grade Squamous Intraepithelial Lesion/Cannot Exclude High Grade Squamous Intraepithelial Lesion (LSIL-H) is a Unique Category of Cytologic Abnormality Associated with Distinctive HPV and Histopathologic CIN2+ Detection Rates. American Journal of Clinical Pathology 2014; 141: 239-246.
  29. Zhao C, Hong W, Li Z, Weng B, Amin M, Austin RM. Human papillomavirus testing and cytologic/ histopathologic "test of cure" follow-up results after excisional treatment for high grade cervical intraepithelial neoplasia. Journal of the American Society for Cytopathology 2014; 3:15-20.
  30. Ganott M, Zuley M, Abrams G, Lu A, Kelly A, Sumkin JH, Chivukula M, Carter G, Austin RM, Bandos A. Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer. ISRN Oncology 2014; Article ID 703160, 9 pages http://dx.doi.org/10.1155/2014/703160
  31. Lum D, Guido R, Rodriguez E, Lee T, Mansuria S, Ambrosio LD, Austin RM. Minimally invasive approach to brush cytology of the fallopian tubes: a feasibility study with implications in ovarian screening. The Journal of Minimally Invasive Gynecology 2014; Apr 5. pii: S1553-4650(14)00212-X. doi:10.1016/j.jmig.2014.03.017. [Epub ahead of print]
  32. Austin RM, Zhao C. Is 58% sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening? CytoJournal 2014; 11: 14.
  33. Castle PE, Zhao C, Austin RM. The Interpretation of LSIL-H. Am J Clin Pathol 2014; 142:278-279.
  34. Davey D, Austin RM, Birdsong G, Zaleski S. The Impact of the Clinical Laboratory Improvement Amendments of 1988 on Cytopathology Practice: A 25th Anniversary review. Journal of the American Society of Cytopathology 2014; 3: 188-198.